Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1 Casper Street DANBURY CT 06810 |
Tel: | N/A |
Website: | https://mannkindcorp.com |
IR: | See website |
Key People | ||
Michael E. Castagna Chief Executive Officer, Director | Steven B. Binder Chief Financial Officer | Christopher B. Prentiss Chief Financial Officer |
Lauren M. Sabella Chief Operating Officer, Executive Vice President | Stuart A. Tross Chief Human Resource Officer, Executive Vice President, Workplace Officer | David B. Thomson Executive Vice President, General Counsel, Secretary |
Burkhard Blank Executive Vice President - Research & Development, Chief Medical Officer | Sanjay Singh Executive Vice President - Technical Operations |
Business Overview |
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). |
Financial Overview |
For the fiscal year ended 31 December 2023, MannKind Corp revenues increased 99% to $199M. Net loss decreased 86% to $11.9M. Revenues reflect Royalties segment increase from $3.1M to $72M, Product sales segment increase of 55% to $126.1M. Lower net loss reflects Interest Income increase from $2.5M to $6.2M (income), Selling - Balancing value decrease of 6% to $49.5M (expense). |
Employees: | 414 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,320M as of Dec 31, 2023 |
Annual revenue (TTM): | $198.96M as of Dec 31, 2023 |
EBITDA (TTM): | $15.25M as of Dec 31, 2023 |
Net annual income (TTM): | -$11.94M as of Dec 31, 2023 |
Free cash flow (TTM): | -$8.35M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $223.54M as of Dec 31, 2023 |
Shares outstanding: | 270,679,296 as of Mar 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |